Intimation pertaining to credit confirmation of Equity Shares from the depositories regarding Sub-Division/Split of Equity Shares of the Company.

Titan Biotech has informed BSE that the sub-division of its equity shares has been completed in the depositories. Each equity share of face value Rs. 10 has been split into 5 equity shares of face value Rs. 2. The new shares have been credited under the updated ISIN INE150C01029, while the old ISIN INE150C01011 has been debited. CDSL processed approximately 28.62 lakh new shares against 5.72 lakh old shares, and NSDL processed about 11.66 lakh new shares against 2.33 lakh old shares, confirming the 1:5 split ratio. The split was executed on February 21, 2026 (CDSL and NSDL batch 1) and February 27, 2026 (NSDL batch 2).